Neurocrine Biosciences, Inc. (NBIX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$144.21+0.72%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $14.7B
- P/E (trailing)
- 21.1
- Forward P/E
- 12.1
- 52-week range
- $122.14 – $186.12
- 52-week change
- +2.69%
- EPS (trailing)
- $6.82
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $2.9B (+21.45%)
- Net income
- $479M
- Operating margin
- 21.6%
- Diluted EPS
- $4.67
- Free cash flow
- $749M
From the company’s annual report on SEC EDGAR.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
Headquarters: San Diego, United States · 2,500 employees · neurocrine.com